Overexpression of Cortactin Increases Invasion Potential in Oral Squamous Cell Carcinoma Shin-ichi Yamada Email author Souichi Yanamoto Goro Kawasaki Akio Mizuno Takayuki K. Nemoto Article First Online: 13 January 2010 Received: 13 August 2009 Accepted: 18 December 2009 DOI :
10.1007/s12253-009-9245-y
Cite this article as: Yamada, S., Yanamoto, S., Kawasaki, G. et al. Pathol. Oncol. Res. (2010) 16: 523. doi:10.1007/s12253-009-9245-y
21
Citations
217
Downloads
Abstract Cortactin, an F-actin binding protein, stabilizes F-actin networks and promotes actin polymerization by activating the Arp2/3 complex. Overexpression of cortactin has been reported in several human cancers. Cortactin stimulates cell migration, invasion, and experimental metastasis. However, the underlying mechanism is not still understood. In the present study, we therefore evaluated the possibility that cortactin could be appropriate as a molecular target for cancer gene therapy. In 70 primary oral squamous cell carcinomas and 10 normal oral mucosal specimens, cortactin expression was evaluated by immunological analyses, and the correlations of the overexpression of cortactin with clinicopathologic factors were evaluated. Overexpression of cortactin was detected in 32 of 70 oral squamous cell carcinomas; significantly more frequently than in normal oral mucosa. Cortactin overexpression was more frequent in higher grade cancers according to T classification, N classifications, and invasive pattern. Moreover, RNAi-mediated decrease in cortactin expression reduced invasion. Downregulation of cortactin expression increased the expression levels of E-cadherin, β-catenin, and EpCAM. The siRNA of cortactin also reduced PTHrP expression via EGF signaling. These results consistently indicate that the overexpression of cortactin is strongly associated with an aggressive phenotype of oral squamous cell carcinoma. In conclusion, we propose that cortactin could be a potential molecular target of gene therapy by RNAi targeting in oral squamous cell carcinoma.
Keywords Cortactin Invasion Metastasis RNA interference Oral squamous cell carcinoma Abbreviations OSCC Oral squamous cell carcinoma
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
PTHrP Parathyroid hormone-related protein
References 1.
Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5:311–316
CrossRef PubMed Google Scholar 2.
Hicks WL Jr, North JH Jr, Loree TR et al (1998) Surgery as a single modality therapy for squamous cell carcinoma of the oral tongue. Am J Otolaryngol 19:24–28
CrossRef PubMed Google Scholar 3.
Sessions DG, Lenox J, Spector GJ et al (2003) Analysis of treatment results for base of tongue cancer. Laryngoscope 113:1252–1261
CrossRef PubMed Google Scholar 4.
González-García R, Naval-Gías L, Rodríguez-Campo FJ et al (2008) Contralateral lymph neck node metastasis of squamous cell carcinoma of the oral cavity: a retrospective analytic study in 315 patients. J Oral Maxillofac Surg 66:1390–1398
CrossRef PubMed Google Scholar 5.
Ziober BL, Silverman SS Jr, Kramer RH (2001) Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 12:499–510
CrossRef PubMed Google Scholar 6.
Bánkfalvi A, Krassort M, Buchwalow IB et al (2002) Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 198:343–351
CrossRef PubMed Google Scholar 7.
Arora S, Kaur J, Sharma C et al (2005) Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 15(11):2272–2284
CrossRef Google Scholar 8.
Yanamoto S, Kawasaki G, Yoshitomi I et al (2007) Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 43:869–877
CrossRef PubMed Google Scholar 9.
Lin M, Smith LT, Smiraglia DJ et al (2006) DNA copy number gains in head and neck squamous cell carcinoma. Oncogene 25:1424–1433
CrossRef PubMed Google Scholar 10.
Hui AB, Or YY, Takano H et al (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65:8125–8133
CrossRef PubMed Google Scholar 11.
Zaharieva BM, Simon R, Diener PA et al (2003) High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 201:603–608
CrossRef PubMed Google Scholar 12.
Meredith SD, Levine PA, Burns JA et al (1995) Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg 121:790–794
PubMed Google Scholar 13.
Schuuring E (1995) The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene 159:83–96
CrossRef PubMed Google Scholar 14.
Merritt WD, Weissler MC, Turk BF et al (1990) Oncogene amplification in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 116:1394–1398
PubMed Google Scholar 15.
Leonard JH, Kearsley JH, Chenevix-Trench G et al (1991) Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 48:511–515
CrossRef PubMed Google Scholar 16.
Williams ME, Gaffey MJ, Weiss LM et al (1993) Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 119:1238–1243
PubMed Google Scholar 17.
Callender T, el-Naggar AK, Lee MS et al (1994) PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 74:152–158
CrossRef PubMed Google Scholar 18.
Fortin A, Guerry M, Guerry R et al (1997) Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: no correlation with subclinical lymph node invasion and disease recurrence. Clin Cancer Res 3:1609–1614
PubMed Google Scholar 19.
Akervall JA, Michalides RJ, Mineta H et al (1997) Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:380–389
CrossRef PubMed Google Scholar 20.
Alavi S, Namazie A, Calcaterra TC et al (1999) Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Laryngoscope 109:874–879
CrossRef PubMed Google Scholar 21.
Rodrigo JP, García LA, Ramos S et al (2000) EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6:3177–3182
PubMed Google Scholar 22.
Xia J, Chen Q, Li B et al (2007) Amplifications of TAOS1 and EMS1 genes in oral carcinogenesis: association with clinicopathological features. Oral Oncol 43:508–514
CrossRef PubMed Google Scholar 23.
Freier K, Sticht C, Hofele C et al (2006) Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer 45:118–125
CrossRef PubMed Google Scholar 24.
Muller D, Millon R, Lidereau R et al (1994) Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. Eur J Cancer B Oral Oncol 30:113–120
CrossRef Google Scholar 25.
Muller D, Millon R, Velten M et al (1997) Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer 33:2203–2210
CrossRef PubMed Google Scholar 26.
Takes RP, Baatenburg de Jong RJ, Schuuring E et al (1997) Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 123:412–419
PubMed Google Scholar 27.
Rodrigo JP, García LA, Ramos S et al (2000) EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6:3177–3182
PubMed Google Scholar 28.
Schuuring E, Verhoeven E, Mooi WJ et al (1992) Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355–361
PubMed Google Scholar 29.
Fantl V, Smith R, Brookes S et al (1993) Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv 18:77–94
PubMed Google Scholar 30.
Karlseder J, Zeillinger R, Schneeberger C et al (1994) Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 9:42–48
CrossRef PubMed Google Scholar 31.
Peters G, Fantl V, Smith R et al (1995) Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 33:125–135
CrossRef PubMed Google Scholar 32.
Weed SA, Parsons JT (2001) Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20:6418–6434
CrossRef PubMed Google Scholar 33.
Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J 382:13–25
CrossRef PubMed Google Scholar 34.
Xiao-Ping H, Tie-Hua R, Peng L et al (2006) Cyclin D1 overexpression in esophageal cancer from southern China and its clinical significance. Cancer Lett 231:94–101
CrossRef PubMed Google Scholar 35.
Bringuier PP, Tamimi Y, Schuuring E et al (1996) Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene 12:1747–1753
PubMed Google Scholar 36.
Rothschild BL, Shim AH, Ammer AG et al (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66:8017–8025
CrossRef PubMed Google Scholar 37.
Luo ML, Shen XM, Zhang Y et al (2006) Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66:11690–11699
CrossRef PubMed Google Scholar 38.
Hsu NY, Yeh KT, Chiang IP et al (2008) Cortactin overexpression in the esophageal squamous cell carcinoma and its involvement in the carcinogenesis. Dis Esophagus 21:402–408
CrossRef PubMed Google Scholar 39.
Strewler GJ, Nissenson RA (1990) Hypercalcemia in malignancy. West J Med 153:635–640
PubMed Google Scholar 40.
Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342:177–185
CrossRef PubMed Google Scholar 41.
Yamada T, Tsuda M, Ohba Y et al (2008) PTHrP promotes malignancy of human oral cancer cell downstream of the EGFR signaling. Biochem Biophys Res Commun 368:575–581
CrossRef PubMed Google Scholar 42.
Lua BL, Low BC (2005) Cortactin phosphorylation as a switch for actin cytoskeletal network and cell dynamics control. FEBS Lett 579:577–585
CrossRef PubMed Google Scholar 43.
Patel AS, Schechter GL, Wasilenko WJ et al (1998) Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 16:3227–3232
CrossRef PubMed Google Scholar 44.
Li Y, Tondravi M, Liu J et al (2001) Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 61:6906–6911
PubMed Google Scholar 45.
Coopman PJ, Do MT, Thompson EW et al (1998) Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin Cancer Res 4:507–515
PubMed Google Scholar 46.
Chen WT (1989) Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool 251:167–185
CrossRef PubMed Google Scholar 47.
Wu H, Parsons JT (1993) Cortactin, an 80/85-kilodalton pp 60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 120:1417–1426
CrossRef PubMed Google Scholar 48.
Helwani FM, Kovacs EM, Paterson AD et al (2004) Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol 164:899–910
CrossRef PubMed Google Scholar 49.
Kovacs EM, Goodwin M, Ali RG et al (2002) Cadherin-directed actin assembly: E-cadherin physically associates with the Arp2/3 complex to direct actin assembly in nascent adhesive contacts. Curr Biol 12:379–382
CrossRef PubMed Google Scholar 50.
Weed SA, Karginov AV, Schafer DA et al (2000) Cortactin localization to sites of actin assembly in lamellipodia requires interactions with F-actin and the Arp2/3 complex. J Cell Biol 151:29–40
CrossRef PubMed Google Scholar 51.
Weaver AM, Karginov AV, Kinley AW et al (2001) Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 11:370–374
CrossRef PubMed Google Scholar 52.
El Sayegh TY, Arora PD, Laschinger CA et al (2004) Cortactin associates with N-cadherin adhesions and mediates intercellular adhesion strengthening in fibroblasts. J Cell Sci 117:5117–5131
CrossRef PubMed Google Scholar 53.
Hoschuetzky H, Aberle H, Kemler R (1994) Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127:1375–1380
CrossRef PubMed Google Scholar 54.
Balzar M, Prins FA, Bakker HA et al (1994) The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 246:108–121
CrossRef Google Scholar 55.
Winter MJ, Nagelkerken B, Mertens AE et al (2003) Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 285:50–58
CrossRef PubMed Google Scholar 56.
Todd R, Wong DT (1999) Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 14:491–500
PubMed Google Scholar 57.
Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832
CrossRef PubMed Google Scholar 58.
Timpson P, Lynch DK, Schramek D et al (2005) Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 65:3273–3280
PubMed Google Scholar 59.
Burtis WJ, Brady TG, Orloff JJ et al (1990) Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106–1112
CrossRef PubMed Google Scholar 60.
Liao J, McCauley LK (2006) Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25:559–571
CrossRef PubMed Google Scholar 61.
Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:446–448
CrossRef PubMed Google Scholar 62.
Kudo Y, Kitajima S, Ogawa I et al (2005) Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 4:471–476
PubMed Google Scholar 63.
Yanamoto S, Iwamoto T, Kawasaki G et al (2005) Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223:67–76
CrossRef PubMed Google Scholar © Arányi Lajos Foundation 2010
Authors and Affiliations Shin-ichi Yamada Email author Souichi Yanamoto Goro Kawasaki Akio Mizuno Takayuki K. Nemoto 1. Department of Oral and Maxillofacial Surgery, Unit of Translational Medicine, Course of Medical and Dental Sciences Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan 2. Department of Oral Molecular Biology, Unit of Basic Medical Sciences, Course of Medical and Dental Sciences Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan